The Council of the Hong Kong Laureate Forum Announced Deferment of Its Inaugural Hong Kong Laureate Forum to November 2022
18.5.2021 11:01:00 EEST | Business Wire | Press release
Given the prevailing situation of the COVID-19 pandemic, the progress of global and local vaccinations, as well as the global position on safe travel, the Board of the Council of the Hong Kong Laureate Forum Limited (the HKLF) has decided after careful consideration that the inaugural Hong Kong Laureate Forum (the Forum), originally scheduled to be held on 15-20 November 2021, would be deferred for one year to November 2022.
Importance of going face-to-face
The Board of the HKLF came to the view that the Forum should ideally be conducted in face-to-face mode given that the main aim of the Forum is to inspire young scientists by providing a platform of direct exchange amongst participating Shaw Laureates and young scientists. However, with the current situation of the pandemic, it is uncertain that safe and unrestricted international travel could be resumed in time for in-person meeting.
Professor Timothy W. TONG, BBS, JP, Chairman of the HKLF, is confident about delivering a successful inaugural Forum next year. He says, “As much as we would have liked to hold this world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit in November this year, it is not a suitable time to do so due to the pandemic. Our Forum aims to inspire young scientists from around the world and provide ample opportunities for exchanges between them and participating Shaw Laureates. We want to ensure that the inaugural Forum fulfils our objective of “Meeting of Inspirational Minds” and I am confident that the inaugural Forum in 2022 will be a great success”.
What happens next
The Secretariat of the HKLF will contact all participating Shaw Laureates and applicants individually as well as their working partners on the deferment. Upon fixing the date of the inaugural Forum next year, all stakeholders will then be notified.
Meanwhile, the Secretariat is planning a series of pre-Forum events targeting different segments of our audience. They would be held over a period of time, starting at end of Q3 this year. These include talk series by renowned scientists and exhibitions on scientific research, etc. Stay tuned to the HKLF website and announcement for details.
Background
The Forum is an annual scientific exchange event organised by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by the Lee Shau Kee Foundation. The major partner of the HKLF is The Shaw Prize Foundation which organises the annual international award, The Shaw Prize.
Website: https://www.hklaureateforum.org
Facebook: https://www.facebook.com/HKLaureateForum
Twitter: https://www.twitter.com/HKLaureateForum
Weibo: https://www.weibo.com/hklaureateforum
LinkedIn: https://www.linkedin.com/company/hklaureateforum/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005468/en/
Contact information
Forum Programme and Participant Enquiry
Ms Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Mr Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom